PMID- 28181725
OWN - NLM
STAT- MEDLINE
DCOM- 20180502
LR  - 20210109
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Print)
IS  - 1462-8902 (Linking)
VI  - 19
IP  - 7
DP  - 2017 Jul
TI  - Treatment patterns in patients with type 2 diabetes mellitus treated with 
      glucagon-like peptide-1 receptor agonists: Higher adherence and persistence with 
      dulaglutide compared with once-weekly exenatide and liraglutide.
PG  - 953-961
LID - 10.1111/dom.12902 [doi]
AB  - AIMS: To compare adherence (proportion of days covered [PDC]), persistence, and 
      treatment patterns among patients with type 2 diabetes mellitus (T2DM) newly 
      initiating glucagon-like peptide-1 receptor agonists (GLP-1RAs). More 
      specifically, the main objectives were to compare dulaglutide vs exenatide once 
      weekly and dulaglutide vs liraglutide. METHODS: Patients with T2DM newly 
      initiating dulaglutide, albiglutide, exenatide once weekly, exenatide twice daily 
      and liraglutide between November 2014 and April 2015 were hierarchically selected 
      from Truven Health's MarketScan Research Databases. Propensity score matching was 
      used to account for selection bias. Adherence to and persistence with the index 
      GLP-1RA, and switching and augmentation patterns were assessed during the 6-month 
      post-index period. RESULTS: Mean adherence for the matched cohorts was 
      significantly higher for dulaglutide than for exenatide once weekly (0.72 vs 
      0.61; P  < .0001) and liraglutide (0.71 vs 0.67; P  < .0001). The percentage of 
      patients achieving PDC >/= 0.80 was significantly higher for dulaglutide compared 
      with exenatide once weekly (54.2% vs 37.9%; P  < .0001) and liraglutide (53.5% vs 
      44.3%; P  < .0001). The mean (standard deviation) days on treatment for all 
      matched patients was significantly higher for patients in the dulaglutide cohort 
      compared with those in the exenatide once-weekly (148.4 [55.4] vs 123.6 [61.6]; P 
       < .0001) and liraglutide cohorts (146.0 [56.9] vs 137.4 [60.1]; P  < .0001). A 
      significantly lower proportion of patients on dulaglutide discontinued treatment 
      compared with those on exenatide once weekly (26.2% vs 48.4%; P  < .0001) and 
      those on liraglutide (28.0% vs 35.6%; P  < .0001). CONCLUSIONS: Dulaglutide 
      initiators had significantly higher adherence, were more persistent, and had 
      lower discontinuation rates compared with initiators of exenatide once weekly or 
      liraglutide during the 6-month follow-up period.
CI  - (c) 2017 Eli Lilly and Company. Diabetes, Obesity and Metabolism published by John 
      Wiley & Sons Ltd.
FAU - Alatorre, Carlos
AU  - Alatorre C
AD  - Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana.
FAU - Fernandez Lando, Laura
AU  - Fernandez Lando L
AD  - Lilly USA, LLC, Lilly Corporate Center, Indianapolis, Indiana.
FAU - Yu, Maria
AU  - Yu M
AD  - Eli Lilly Canada Inc., Toronto, Ontario, Canada.
FAU - Brown, Katelyn
AU  - Brown K
AD  - Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana.
FAU - Montejano, Leslie
AU  - Montejano L
AD  - Truven Health Analytics, an IBM Company, Ann Arbor, Michigan.
FAU - Juneau, Paul
AU  - Juneau P
AD  - Truven Health Analytics, an IBM Company, Ann Arbor, Michigan.
FAU - Mody, Reema
AU  - Mody R
AD  - Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana.
FAU - Swindle, Ralph
AU  - Swindle R
AD  - Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Observational Study
DEP - 20170316
PL  - England
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Immunoglobulin Fc Fragments)
RN  - 0 (Peptides)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 0 (Venoms)
RN  - 62340-29-8 (Glucagon-Like Peptides)
RN  - 839I73S42A (Liraglutide)
RN  - 9P1872D4OL (Exenatide)
RN  - WTT295HSY5 (dulaglutide)
SB  - IM
MH  - Aged
MH  - Cohort Studies
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy/metabolism
MH  - Drug Administration Schedule
MH  - Drug Monitoring
MH  - Drug Prescriptions
MH  - Exenatide
MH  - Female
MH  - Follow-Up Studies
MH  - Glucagon-Like Peptide-1 Receptor/*agonists/metabolism
MH  - Glucagon-Like Peptides/administration & dosage/adverse effects/*analogs & 
      derivatives/therapeutic use
MH  - Humans
MH  - Hypoglycemic Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Immunoglobulin Fc Fragments/administration & dosage/adverse effects/*therapeutic 
      use
MH  - Kaplan-Meier Estimate
MH  - Liraglutide/administration & dosage/adverse effects/*therapeutic use
MH  - Male
MH  - Medication Adherence
MH  - Middle Aged
MH  - Peptides/administration & dosage/adverse effects/*therapeutic use
MH  - *Practice Patterns, Physicians'
MH  - Recombinant Fusion Proteins/administration & dosage/adverse effects/*therapeutic 
      use
MH  - Retrospective Studies
MH  - United States
MH  - Venoms/administration & dosage/adverse effects/*therapeutic use
PMC - PMC5485056
OTO - NOTNLM
OT  - adherence
OT  - augmentation
OT  - glucagon-like peptide-1 receptor agonists
OT  - persistence
OT  - real-world evidence
OT  - switching
OT  - type 2 diabetes mellitus
EDAT- 2017/02/10 06:00
MHDA- 2018/05/03 06:00
PMCR- 2017/06/27
CRDT- 2017/02/10 06:00
PHST- 2016/10/31 00:00 [received]
PHST- 2017/01/23 00:00 [revised]
PHST- 2017/02/05 00:00 [accepted]
PHST- 2017/02/10 06:00 [pubmed]
PHST- 2018/05/03 06:00 [medline]
PHST- 2017/02/10 06:00 [entrez]
PHST- 2017/06/27 00:00 [pmc-release]
AID - DOM12902 [pii]
AID - 10.1111/dom.12902 [doi]
PST - ppublish
SO  - Diabetes Obes Metab. 2017 Jul;19(7):953-961. doi: 10.1111/dom.12902. Epub 2017 
      Mar 16.